

# Disease Analyzer - OMOP

**First published:** 01/02/2024

**Last updated:** 18/04/2024

Data source

Primary care medical records

## Administrative details

### Administrative details

**PURI**

<https://redirect.ema.europa.eu/resource/1111130>

---

**Data source ID**

1111130

---

**Data source acronym**

DA France

---

**Data holder**

[IQVIA](#)

---

**Data source type**

Primary care medical records

---

**Main financial support**

Funding by own institution

Funding from industry or contract research

---

**Care setting**

Primary care – GP, community pharmacist level

---

**Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

---

#### Data source website

<https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights>

## Contact details

Sarah Seager

Main

[sarah.seager@iqvia.com](mailto:sarah.seager@iqvia.com)

## Data source regions and languages

#### Data source countries

France

---

#### Data source languages

French

## Data source establishment

#### Data source established

15/06/1997

---

#### Data source time span

**First collection:** 01/01/2012

The date when data started to be collected or extracted.

## Publications

### Data source publications

[Association of Hemoglobin A1c Levels with Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes Treated With Metformin Analysis From the Observational Health Data Sciences and Informatics Initiative JAMA Network Open. 2018;1\(4\):e181755.](#)

## Studies

## List of studies that have been conducted using the data source

Prescribing of zolpidem in the primary care setting in France, Germany and the UK during 2012. (Prescribing of zolpidem in IMS Germany/France/UK)

A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Non-steroidal Anti-inflammatory Therapies in a Cohort of Patients with Ankylosing Spondylitis (AS) in the UK, France and Germany (MK-0663-163)

Indications for systemic fluoroquinolone prescribing in Europe: a descriptive population based study

Tramadol prescribing: a drug utilisation study using electronic data from France, Germany and the UK

A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases

Use of ondansetron in pregnant female patients in the IMS Disease Analyzer databases in France and Germany (Ondansetron use pregnancy)

Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study

Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)

Trends in prescriptions of valproate and valpromide for bipolar disorder in IMS France and IMS Germany between 2010 and June 2016 and in UK THIN between 1999 and 2015

Prevalence of hypereosinophilic syndrome (HES) in the paediatric population in EU (Hypereosinophilic syndrome in children)

Glucocorticoid-induced osteoporosis (GIOP): prescription patterns of glucocorticoids in paediatric patients

Prevalence of narcolepsy in two European countries - France and Germany

Incidence rates of morphea, systemic sclerosis and scleroderma

Background incidence rates of Interstitial Lung Disease

Population incidence rates of pemphigoid in six European countries

Immune thrombocytopenia following vaccination with DTaP-IPV or TdaP-IPV in children

Prevalence of palmoplantar psoriasis and pustular psoriasis in children

Drug utilisation study of macrolide-containing medicinal products during pregnancy

Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers

Prevalence of multiple myeloma

Prevalence of immunocompromised patients with a diagnosis of cytomegalovirus infection

Prevalence of Acute Liver Injury

Incidence of phimosis and paraphimosis in patients treated with SGLT2 inhibitors

DARWIN EU® - Characterising interstitial lung disease in Europe

## Data elements collected

### The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

---

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

---

#### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

---

#### **Hospital admission and/or discharge**

No

---

#### **ICU admission**

Is information on intensive care unit admission available?

No

---

#### **Cause of death**

Not Captured

---

## **Prescriptions of medicines**

Captured

---

## **Prescriptions vocabulary**

RxNorm

---

## **Dispensing of medicines**

Captured

---

## **Dispensing vocabulary**

other

RxNorm

---

## **Advance therapy medicinal products (ATMP)**

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

No

---

## **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

---

## **Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

---

## **Indication vocabulary**

SNOMED

---

## **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

---

## **Administration of vaccines**

No

---

## **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

---

## Procedures vocabulary

SNOMED

---

### Healthcare provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

---

### Clinical measurements

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

---

### Genetic data

Are data related to genotyping, genome sequencing available?

Not Captured

---

### Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

---

### Biomarker data vocabulary

Other

---

### Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

---

### Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

---

### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

---

### Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

---

**Diagnostic codes**

Captured

---

**Diagnosis / medical event vocabulary**

SNOMED

---

**Medicinal product information**

Captured

---

**Medicinal product information collected**

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

---

**Medicinal product vocabulary**

RxNorm

---

**Quality of life measurements**

Captured

---

**Quality of life measurements vocabulary**

Not coded (Free text)

---

**Lifestyle factors**

Captured

---

**Lifestyle factors**

Other

---

**Sociodemographic information**

Captured

---

**Sociodemographic information collected**

Gender

---

Quantitative descriptors

Population Qualitative Data

## Population age groups

Paediatric Population (< 18 years)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (? 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Estimated percentage of the population covered by the data source in the catchment area

3%

---

## Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

General population

## Population

### Population size

6285423

## Active population

### Active population size

947234

## Median observation time

### Median time (years) between first and last available records for unique individuals captured in the data source

229.00

---

### Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

1338.00

## Data flows and management

## Access and validation



### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

<https://www.pharmacoepi.org/resources/policies/guidelines-08027/>

### **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

---

### **Access to subject details**

Can individual patients/practitioners/practices included in the data source be contacted?

No

---

### **Description of data collection**

Anonymized patient records collected from patient management software used by GPs to document patients' clinical records

## **Event triggering registration**

### **Event triggering registration of a person in the data source**

Practice registration

---

### **Event triggering de-registration of a person in the data source**

Death

Emigration

Loss to follow up

Practice deregistration

## **Data source linkage**

### **Linkage**

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

## **Data management specifications that apply for the data source**

### **Data source refresh**

Quarterly

---

## Informed consent for use of data for research

Not Required

---

## Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

---

## Data source preservation

Are records preserved in the data source indefinitely?

No

---

## Data source preservation length (years)

10 years

---

## Approval for publication

Is an approval needed for publishing the results of a study using the data source?

No

---

## Data source last refresh

01/12/2022

# Common Data Model (CDM) mapping

## CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

## CDM Mappings

### CDM name

OMOP

---

### CDM website

<https://www.ohdsi.org/Data-standardization/>

## Data source ETL CDM version

5.3.1

---

## Data source ETL frequency

4,00 months

---

**Data source ETL status**  
Completed